This story is from the BioSpectrum Asia Nov 2024 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the BioSpectrum Asia Nov 2024 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Empowering Women in STEM: Viet Nam's Journey Towards Innovation and Equality
2025 marks the 10th anniversary of the International Day of Women and Girls in Science (IDWGS) (observed on February 11) and the 30th anniversary of the Beijing Declaration and Platform for Action, two significant milestones in the global effort to promote gender equality and women's empowerment. Recognising the importance of gender inclusivity, Viet Nam has taken major policy steps to empower female researchers and entrepreneurs. By investing in education, policy reforms, and celebrating the achievements of women scientists, the country is setting a global example for inclusive development.
ADCS on the rise: A Trojan Horse Race for Patients
Antibody-Drug Conjugates (ADCs) have emerged as a major therapeutic approach creating new opportunities for a range of cancer treatments. The recent scientific and clinical progress in the ADC field underscores its importance for ongoing research.
A Wake-Up Call for International Women's Day
International Women's Day (IWD) (celebrated on March 8) has been around for over a hundred years, as have many of the issues still impacting women's advancement. Since 1911, IWD belongs to all who care about women's equality. At the current rate of progress, it will take until 2158, which is roughly five generations from now, to reach full gender parity, according to data from the World Economic Forum. Focusing on the need to Accelerate Action (theme for IWD 2025) emphasizes the importance of taking swift and decisive steps to achieve gender equality. Talking about the status of women in Australian life sciences space, the article calls for an action for better health, great businesses and a stronger economy.
Collaboration vs.Competition: Patent Cliffs
The biosimilar business is growing increasingly fragmented among smaller firms, even as larger corporations are merging. Biosimilars are being developed by more than 40 smaller companies, many of which have no prior experience in the field. Long-term viability and supply reliability are threatened by this fragmentation.
"Biotech sector in Taiwan moves fast, making it easier to pivot and innovate"
Caliway Biopharmaceuticals has recently announced the completion of its initial public offering (IPO) and up-listing from the Emerging Stock Market to the Taipei Exchange (TWSE-6919). The round raised approximately $206 million (NT$6.4 billion), marking it the largest IPO in Taiwan's biotech industry history and valuing the company at nearly $3 billion. The company is poised for a transformation in 2025, advancing its groundbreaking clinical programmes and strengthening its global market presence. Following its recent record-breaking IPO, BioSpectrum Asia took an opportunity to speak with Vivian Ling, Chief Executive Officer & Chief R&D Officer, Caliway Biopharmaceuticals to explore their innovative contributions in biopharmaceuticals. Edited excerpts:
"Personalised medicine is now a reality, not just an aspiration"
Terumo Blood and Cell Technologies, (a subsidiary of Terumo Corporation, Japan) is at the forefront of advancing blood- and cell-based therapies. In an interview with BioSpectrum Asia, Antoinette Gawin, President and CEO,Terumo Blood and Cell Technologies outlines the company’s current strategy, key projects, the importance of the APAC region, and her perspective on evolving trends in the industry.
Rise of ADCs: Expanding Applications and the Road to Commercialisation
The development of antibody-drug conjugates (ADCs) has advanced significantly in the biopharmaceutical sector; in the last five years, eight of the 14 ADCs that are currently approved have obtained regulatory approval. The quantity of pre-clinical to commercial ADC compounds in the innovative modality pipeline increased by more than 25 per cent year over year, according to a market trend. ADCs have the potential to transform targeted medicine and give patients everywhere new hope with further development and wise funding.
Mitigating PATENT CLIFF Fallout
Monoclonal antibodies (mAbs) represent a $279.8 billion market, projected to reach $804 billion by 2033, according to a report from Dimension Market Research. With patents for many of these valuable drugs set to expire in the coming years, the industry faces significant challenges. In this story, we examine 11 blockbuster mAbs whose patents will expire between 2025 and 2030. These expirations, affecting some of pharma's biggest players, will have a major impact on the market and their revenue streams.
How Degrader-Antibody Conjugates Are Transforming Precision Medicine for Oncology & Beyond
Targeted cancer therapy has advanced significantly with the creation of Degrader-antibody conjugates (DACs). The shortcomings of conventional ADCs are addressed by DACs, which combine the specificity of antibodies with the special capacity of protein degraders to eradicate important oncogenic drivers.
Trump's Executive Order Impinges WHO Ops
The United States has announced its withdrawal from the World Health Organization (WHO), a move that raises significant concerns due to the US being its largest donor, contributing nearly 18 per cent of the funding. This decision creates a major funding gap for the WHO. What immediate actions will the organisation and its member states take to address this shortfall, and how might it reshape the global leadership landscape in health governance? Let's find out.
